Business Wire

Valeo Foods Group Acquires Melegatti Cakes Expanding the Italian Bakery Portfolio

Share

Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the assets of an Italian panettone, pandoro and croissant producer, Melegatti 1894 S.p.A.This acquisition is another step forward in Valeo Foods Groups’ strategy to expand its baked sweet treats portfolio, and reinforces Valeo’s commitment to bringing authentic Italian confections and established regional brands to a wider international audience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702677156/en/

Melegatti

Founded in 1894 in Verona, Melegatti has a strong reputation for artisanal cakes - particularly pandoro, panettone and filled croissants - traditional recipes, and a rich Italian heritage, Melegatti has a proud legacy founded on family values, craftsmanship, and a passion for quality.

“We are excited to welcome Melegatti into the Valeo Foods Group,” said Ronald Kers, Group CEO. “This acquisition marks a significant strategic step in expanding our portfolio of high-quality, well-known brands and underscores our commitment to excellence, innovation, and long-term value creation. As we integrate Melegatti into our business, we strengthen our presence in South-West Europe and open new avenues for growth across our global network — all while bringing authentic, high-quality Italian bakery treats to consumers around the world.”

The acquisition will also enable Valeo Foods Group to strengthen its manufacturing and logistics capabilities, adding capacity to meet increasing demand while preserving the distinctive character and authenticity of Melegatti’s products.

Roberto Spezzapria, President of Melegatti, said, "Following the successful relaunch of the historic Melegatti brand in the Italian market, we are proud to entrust its future to the experience and expertise of Valeo Foods Group. We are confident that Valeo Foods will guide the brand into its next phase of international growth, while further strengthening its value and honouring its deep roots in Italian culture.”

Alberto Alfieri, CEO Valeo Foods, South-West Europe, added “Melegatti is built on craftsmanship and care - values that strongly align with our own. This means that we can preserve what makes Melegatti special while continuing to grow sustainably, bringing another example of Italian food tradition and excellence to the global market. It’s an exciting new chapter for our team and our customers.”

About Melegatti 1884 S.p.A

Melegatti 1884 S.p.A. is an Italian confectionery producer specializing in Pandoro, Panettone, croissants, and other sweet bakery goods. Production takes place across two facilities located in San Giovanni Lupatoto and San Martino Buon Albergo, both in the province of Verona.

Founded in 1894 in Verona by Domenico Melegatti, the inventor of the original Pandoro, which he patented in the same year, the company has over 130 years of history and remains a symbol of Italian holiday tradition. Known for its artisanal recipes and slow leavening process, Melegatti blends traditional craftsmanship with modern production.

About Valeo Foods Group

Valeo Foods Group is one of Europe’s fastest-growing food companies, specialising in sweets, snacks, and treats. Home to over 90 brands including Balconi cakes and wafers, Pedro confectionary, Mila, Lina and Horalky wafers, Rowse Honey, Bernard maple syrup, Barratt’s sweets, Fox’s mints and Kettle Chips. We operate in over 100 countries serving major retailers, discounters, e-commerce, convenience stores, wholesalers, and foodservice operators. With revenues exceeding €1.8 billion, we employ nearly 6,000 people across 30 facilities in the UK, Italy, Germany, the Netherlands, Ireland, Slovakia, Czech, and Canada. Valeo Foods Group is owned by Bain Capital.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702677156/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of Xella to Holcim20.10.2025 06:40:00 CEST | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund X, LP of a binding agreement to sell Xella Group (“Xella”), a leading provider of walling solutions, to Holcim, the leading partner for sustainable construction. The transaction values Xella at approximately €1.85 billion. Headquartered in Duisburg, Germany, Xella is a European provider of efficient and sustainable walling solutions for the entire house shell, operating brands such as Ytong, Silka, Hebel and Multipor. The company employs more than 4,000 team members. In partnership with Lone Star, Xella has taken significant strides in recent years to optimize its offering by strategically focusing the business on walling solutions, while also enhancing its commercial and digital capabilities. Under Lone Star’s stewardship, Xella has also continued to progress its sustainability initiatives. Today, the business stands as a market leader in its sector with a strong reputation for a people-first c

Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products20.10.2025 06:00:00 CEST | Press release

Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the market introduction of several additions to its MOSS!MODULARITY™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019799867/en/ MOSS!MODULARITY Injection Screw MOSS!MODULARITY encompasses a broad range of products and technologies for spinal surgery based around the concept of providing an advanced modular workflow for posterior stabilization and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and offers several advantages over working with traditional pre-assembled pedicle screws, e.g.: Improved visualisation and access to the surgical working space; Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads; Increased surgic

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye